Rhythm Pharmaceuticals to Present at Investor Conferences in September
28 août 2023 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France
07 août 2023 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment ---- Early access designation for hypothalamic obesity comes in addition...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
04 août 2023 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update
01 août 2023 07h00 HE
|
Rhythm Pharmaceuticals, Inc.
-- Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE® (setmelanotide) -- -- Strong U.S. commercial progress continues with more than 125 new prescriptions for...
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
19 juil. 2023 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
17 juil. 2023 06h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
13 juil. 2023 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
17 juin 2023 14h01 HE
|
Rhythm Pharmaceuticals, Inc.
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks -- -- Phase 3 trial evaluating setmelanotide in...
Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference
07 juin 2023 08h00 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
06 juin 2023 16h01 HE
|
Rhythm Pharmaceuticals, Inc.
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...